Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
|Videos|January 19, 2017
Drug Cost Growth Changing the Specialty Pharmacy Patient Experience
Author(s)Lauren Santye, Assistant Editor
Marc O'Connor, CEO and chief strategy officer of Curant Health, discusses how projected drug spending growth will alter the specialty pharmacy landscape in the future.
Advertisement
Marc O'Connor, CEO and chief strategy officer of Curant Health, discusses how projected drug spending growth will alter the specialty pharmacy landscape in the future.
Advertisement
Related to this article
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
2
What the 2025-2030 Dietary Guidelines Mean for Heart Health
3
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
4
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
5